These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33948925)

  • 1. Evaluation of the Octreotide Acetate Pen Injector and its Instructions for Use in a Formative Human Factors Study.
    Andre A; Squittieri N; Patil SB
    Adv Ther; 2021 Jun; 38(6):3129-3142. PubMed ID: 33948925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating Use of the Octreotide Acetate Pen Injector in a Summative Human Factors Validation Study.
    Andre A; Squittieri N; Patil S
    Endocr Pract; 2022 Apr; 28(4):414-419. PubMed ID: 35123070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usability of devices for self-injection: results of a formative study on a new disposable pen injector.
    Lange J; Richard P; Bradley N
    Med Devices (Auckl); 2014; 7():195-203. PubMed ID: 24966698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. US human factors engineering evaluation of an updated follitropin alfa pen injector (GONAL-f® RFF Redi-ject®) and instructions for use.
    Mahony M; Dwyer A; Barkume R; Strochlic A; Jeannerot F; Stüdeli T
    Expert Opin Drug Deliv; 2018 Jan; 15(1):5-15. PubMed ID: 29198148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formative usability evaluation of a fixed-dose pen-injector platform device.
    Lange J; Nemeth T
    Med Devices (Auckl); 2018; 11():105-112. PubMed ID: 29670411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usability engineering study in the European Union of a redesigned follitropin alfa pen injector for infertility treatment.
    Jeannerot F; Stüdeli T; Gunther-LaVergne L; Hirning D; Schertz J
    Expert Opin Drug Deliv; 2016 Sep; 13(9):1221-9. PubMed ID: 27329677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the usability and safety of the semaglutide single-dose pen-injectors through summative (human factors) usability testing.
    Klonoff DC; Bassock S; Dwyer A; Engels E; Qvist M; Sparre T; Snitker S
    J Diabetes Investig; 2021 Jun; 12(6):978-987. PubMed ID: 33034163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of training in effective simulated self-injection of subcutaneous depot medroxyprogesterone acetate: observations from a usability study.
    Kaplan I; Ross D; Hilton F; Morgenstern D; Wolter K
    Contraception; 2016 Oct; 94(4):314-20. PubMed ID: 27241898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Concizumab Pen-Injector is Easy to Use and Preferred by Hemophilia Patients and Caregivers: A Usability Study Assessing Pen-Injector Handling and Preference.
    Kahr Rasmussen N; Berg B; Christiansen ASL; Neergaard JS; Ter-Borch G; Hildebrand EA; Gonczi M; Sparre T
    Patient Prefer Adherence; 2024; 18():1713-1727. PubMed ID: 39161804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and usability of a new subcutaneous auto-injector device to administer hydroxyprogesterone caproate to reduce the risk of recurrent preterm birth.
    Travanty MN; Calawa B; Shalaby WS; Jozwiakowski MJ; Haraldsen KB
    Med Devices (Auckl); 2018; 11():241-252. PubMed ID: 30100767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injecting without pressing a button: An exploratory study of a shield-triggered injection mechanism.
    Zijlstra E; Coester HV; Heise T; Plum-Mörschel L; Rasmussen O; Rikte T; Pedersen LK; Qvist M; Sparre T
    Diabetes Obes Metab; 2018 May; 20(5):1140-1147. PubMed ID: 29369493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience.
    Fujioka K; Sparre T; Sun LY; Krogsgaard S; Kushner RF
    J Diabetes Sci Technol; 2015 Jul; 10(1):164-74. PubMed ID: 26183599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summative Usability Evaluation of the SCTE-AI Device: A Novel Prefilled Autoinjector for Subcutaneous Testosterone Administration.
    Arora S; Moclair B; Murphy K; Jaffe JS; Kaminetsky JC
    J Sex Med; 2018 Dec; 15(12):1707-1715. PubMed ID: 30393104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semaglutide single-dose pen-injector: Post hoc analysis of summative usability testing for weight management.
    Klonoff DC; Bassock S; Engels E; Frederiksen M; Marber M; Qvist M; Sparre T; Snitker S
    Diabetes Obes Metab; 2021 Nov; 23(11):2590-2594. PubMed ID: 34338402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pen device for injection of recombinant human growth hormone: a European usability engineering study.
    Cachemaille A; Warren SE; Moss S
    Expert Opin Drug Deliv; 2020 Jul; 17(7):1041-1048. PubMed ID: 32543910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functionality of a novel follitropin alfa pen injector: results from human factor interactions by patients and nurses.
    Saunders H; de la Fuente Bitaine L; Eftekhar C; Howles CM; Glaser J; Hoja T; Arriagada P
    Expert Opin Drug Deliv; 2018 Jun; 15(6):549-558. PubMed ID: 29595399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient evaluation of the redesigned follitropin alfa pen injector.
    Schertz J; Worton H
    Expert Opin Drug Deliv; 2017 Apr; 14(4):473-481. PubMed ID: 28140682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human factors engineering and design validation for the redesigned follitropin alfa pen injection device.
    Mahony MC; Patterson P; Hayward B; North R; Green D
    Expert Opin Drug Deliv; 2015 May; 12(5):715-25. PubMed ID: 25895897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimum method for administration of biosynthetic human growth hormone: a randomised crossover trial of an Auto Injector and a pen injection system.
    Stanhope R; Albanese A; Moyle L; Hamill G
    Arch Dis Child; 1992 Aug; 67(8):994-7. PubMed ID: 1520018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing drug self-injection errors: a randomized trial comparing a "standard" versus "plain language" version of Patient Instructions for Use.
    Smith MY; Wallace LS
    Res Social Adm Pharm; 2013; 9(5):621-5. PubMed ID: 23506652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.